It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (NYSE: ABBV). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to ...

In the latest market close, AbbVie (ABBV) reached $170.16, with a -1.64% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 2.36% for the day.

AbbVie is poised to grow this year for the first time since Humira's U.S. patent expired. The dividend yields a generous 3.7% and features decades of consistent growth. While tariffs, politics ...

AbbVie has had a dramatic year, juggling a Humira hangover, political landmines, and a costly failed drug trial. Despite a major flop on a $9 billion acquisition, AbbVie’s new immunology duo, Skyrizi ...

There is change at the top of AbbVie’s R&D organisation, as chief scientific officer Thomas Hudson announces his retirement after four years in the role. He will be replaced as head of AbbVie ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

US drug maker AbbVie has launched its key leukemia drug, Venetoclax, in India, marking its entry into the country's oncology market as it seeks to address the challenges of treating Acute Myeloid ...